$DERM

Journey Medical (DERM) rose 13% on strong Q2 results, with revenue up 23% to $18.5M. Iovance (IOVA) gained 11% on 66% revenue growth to $99.3M. Caris (CAI) advanced 8% after raising 2026 revenue guidance to $1.03B-$1.04B. Prelude (PRLD) up 8% on narrower Q2 loss. Compugen (CGEN) gained 7% on COM701 trial progress. Conexeu (CNXU) rose 4% on regenerative aesthetics market opportunity.

Journey Medical Corporation reported Q2 2026 positive EBITDA, with total net product revenue up 23% year over year and flat operating expenses. Amrozi revenue was $8.1M, helped by higher prescriptions and ASP gains from more reimbursed channels. Management expects 2026 cash flow positivity, improved formulary coverage, and a July 2026 Urox Cream launch.

Journey Medical Corp (DERM) shares rose 10.9% pre-open after it reported Q2 2026 results. Adjusted EPS was $0.10 vs a $0.02 loss estimate, and revenue was $18.5M vs $18.37M forecast, up 23% YoY. Emrosi sales were $8.1M; GAAP net loss narrowed to about $312k. Company expects positive adjusted EBITDA for 2026.

Journey Medical Corp (DERM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Journey Medical Corporation Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights Total revenues were $18.5 million for the second quarter of 2026, reflecting 23% growth from the prior-year quarter Emrosi ® revenues were $8.1 million for the s

Journey Medical Corp (DERM) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001867066 0001867066 2026-06-24 2026-06-24 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of repor

Journey Medical Corp (DERM) is experiencing a period of high volatility, with recent short-term gains but a long-term downward trend. The company's stock performance over the past year shows a significant decline, reflecting skepticism about its growth and financial management despite some analyst "buy" ratings from smaller firms. Investors are advised to be cautious, as the stock sits at an inflection point, requiring clear evidence of sustained revenue growth and operational improvements to justify a higher valuation.

While the top- and bottom-line numbers for Journey Medical (DERM) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Journey Medical (DERM) delivered earnings and revenue surprises of -12.50% and -0.39%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Company to host conference call to discuss financial results and provide a corporate update on November 12, 2025 at 4:30 p.m. ET Company to host conference call to discuss financial results and provide a corporate update on November 12, 2025 at 4:30 p.m. ET ...

FDA-approved Emrosi ( 40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release ) is available in the United States for the treatment of inflammatory lesions of rosacea in adults